Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous...
Myeloma NZ
Lenalidomide-related Progressive Multifocal Leukoencephalopathy: A Case Report and Review of Drug-related Cases in Multiple Myeloma
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the central nervous system caused by reactivation of John...
Improved Clinical Outcomes in Relapsed/Refractory Multiple Myeloma With Daratumumab Re-Treatment
This story was originally published on the Hematology Advisor The introduction of monoclonal antibodies and immunomodulators into earlier lines of...
New medicine for multiple myeloma shows promising results
A new drug reduced the risk of relapse and increased survival by five months, according to a recent study. The results were presented at a cancer...
New Zealand falling behind rest of world in cancer treatment, according to new myeloma report
Originally published on Health Industry Hub The management of New Zealand’s most common blood cancer, myeloma, is falling behind the rest of the...
New Zealand lacks treatment access to myeloma patients – Myeloma New Zealand
This story was originally published on RNZ An advocate group is warning that New Zealanders are dying from a common blood cancer because they've...
NZ falling behind rest of world in cancer treatment – Myeloma NZ
The management of New Zealand’s most common blood cancer, myeloma, is falling behind the rest of the world, putting lives at unnecessary risk of...
New Zealand lacking best treatment options for blood cancer patients, warns Myeloma NZ
This story was originally published on the NZ Herald Kiwis diagnosed with the country's most common form of blood cancer are being put at...
Innovation Fuels Survival Gains in Multiple Myeloma
In the past 20 years, we’ve been very fortunate in the development of effective myeloma therapies and have seen remarkable progress for our...
Daratumumab cuts risk for progression in multiple myeloma
For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk...
Multiple Myeloma Research Review
Highlights include: • Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. • MGUS risk in relatives of patients with multiple...